Azithromycin enhances the cytotoxicity of DNA‐damaging drugs via lysosomal membrane permeabilization in lung cancer cells

• Published in: Cancer science Vol. 112; no. 8; pp. 3324 - 3337
• Main Authors: Toriyama, Kazutoshi, Takano, Naoharu, Kokuba, Hiroko, Kazama, Hiromi, Moriya, Shota, Hiramoto, Masaki, Abe, Shinji, Miyazawa, Keisuke
• Format: Journal Article
• Language: English
• Published: Tokyo John Wiley & Sons, Inc 01.08.2021; John Wiley and Sons Inc
• Subjects: Apoptosis; Autophagy; Azithromycin; Cancer therapies; Carboplatin; Cell death; Chemotherapy; CRISPR; Cytotoxicity; Deoxyribonucleic acid; DNA; DNA damage; Doxorubicin; Drug dosages; Etoposide; Experiments; Flow cytometry; Gene expression; Kinases; Lung cancer; Lysosomal enzymes; lysosomal membrane permeabilization; Lysosomes; Macrolide antibiotics; Mutation; Non-small cell lung carcinoma; non–small‐cell lung cancer; Original; p53; Phagocytosis; Proteasome inhibitors; Protein-tyrosine kinase; Proteins

Cancer cells use autophagy for growth, survival, and cytoprotection from chemotherapy. Therefore, autophagy inhibitors appear to be good candidates for cancer treatment. Our group previously reported that macrolide antibiotics, especially azithromycin (AZM), have potent autophagy inhibitory effects,...